You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201311 - 201320 of 205043 results
  1. Phase II of VerOFy: A New Tool to Improve Productivity for Stress Research

    SBC: PRESAGE BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): With few exceptions, extensive characterization of signal pathway alterations in cancer, and advances in our capacity to identify potent modulators of distinct molecular targets, has not translated into breakthrough drugs. In a recent New York Times article (Nov. 14, 2009), Mervyn Turner, Chief Strategy Officer for Merck was quoted: We invest far too long in b ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa

    SBC: ORGANIX CHEMISTRY SOLUTIONS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metastasis primarily target tumor growth. These drugs produceonly modest increases in survival in patients with aggressive metastatic cancers and have significant side effects. Currently, there are no avail ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: Planet Biotechnology Incorporated            Topic: NCI

    DESCRIPTION (provided by applicant): Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism by which therapeutic monoclonal antibodies (mAbs) kill tumor cells. However, killing by current therapeutic IgG mAbs is not optimal. InefficientADCC provides a potential escape mechanism for tumors and can be targeted to improve antibody- based cancer therapies. Most of the tumor-directe ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Label-free platform for applications in drug discovery

    SBC: VST LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The primary sequelae resulting from radical mastectomy and sentinel lymph node removal during the treatment of breast cancer is the development of lymphedema in related limbs. Estimates of the frequency of post-cancer lymphedema range from 20%-90%, depending upon the metrics used to measure development of the condition. There is significant social and monetary ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. NIH Phase II-UNCD as Bio-Inert Interface for Anti-Thrombogenicity Applications in

    SBC: Lucidicor Inc.            Topic: NCI

    DESCRIPTION: Protein kinases are chemically tractable drug targets, yet less than 5% of the human kinome has been thoroughly explored with selective small molecule inhibitors to demonstrate their therapeutic utility. Pharmaceutical companies are interested in evaluation of the therapeutic potential of targeting kinases to define new opportunities to address unmet medical needs. Lucidicor, Inc. h ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease

    SBC: XL Sci Tech Inc            Topic: NCI

    DESCRIPTION (provided by applicant): Current practice in the USA for inoperable esophageal cancer is a palliative treatment using metal stent for end-stage cancer patients. Outside the USA (especially in Far East countries including China and Korea), therehave been reported clinical benefits of attaching sealed sources such as prostate seeds to the outside of an esophageal stent. Although simple a ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Protease chain reactions for molecular analysis of cancer markers

    SBC: AGILTRON, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Intraoperative imaging techniques are used by neurosurgeons in the treatment for primary brain tumors such as gliomas to achieve maximal surgical resection of pathological tissue while leaving essential areas intact. Current imaging techniques include magnetic resonance imaging (MRI), computed tomography (CT), x-ray fluoroscopy, and ultrasound. Their wide use i ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: IMMUNOMEDICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The overall goal of this SBIR application is to initiate a clinical trial with a bispecific antibody (bsMAb) pretargeting procedure for detecting pancreatic carcinoma, based on a highly specific antibody (PAM4) recognizing an epitope found in pancreatic mucin. The pretargeting procedure has been shown pre-clinically and clinically to be highly sensitive and mo ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Intraoperative imaging of breast cancer margins using Polarization Subtraction Te

    SBC: LUMAMED, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): LumaMed LLC proposes developing LumaScan , an innovative, cost effective and easy to use device for visualizing tumor margins during Breast Conservation Surgery (BCS), a method that is used in about 60-70% percent of breast cancer surgeries. Currently, breast tumors are approximately located using methods such as MRI or CT in a preoperative procedure. During s ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Semi-targeted Immuno-Therapeutic Approach for Treatment of Obesity

    SBC: Diffregen, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase 1 SBIR project is to perform go-/no-go evaluation of the proprietary protein, angiocidin, as a novel therapy for the treatment of acute myeloid leukemia (AML). AML is a significant medical burden as existingtherapy based on cytotoxic drugs has a low efficacy rate and is contraindicated in many elderly people, who comprise the largest and fastest grow ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government